Jingxin Mo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jingxin Mo has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Bing Lu
Key Laboratory for Stem Cells and Tissue Engineering, Ministry of Education, Sun Yat-sen University Guangzhou, China
1 shared publication- Wei Zhao
Center for Stem Cell Biology and Tissue Engineering, Key Laboratory for Stem Cells and Tissue Engineering, Ministry of Education, Sun Yat-Sen University, Guangzhou, China
1 shared publication Xiaojia Huang
Key Laboratory for Stem Cells and Tissue Engineering, Ministry of Education, Sun Yat-sen University Guangzhou, China
1 shared publication
Latest Publications
- Open Access
- 12 April 2016
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 7, 84
Drug Delivery Using Nanoparticles for Cancer Stem-Like Cell Targeting
The theory of cancer stem-like cell (or cancer stem cell, CSC) has been established to explain how tumor heterogeneity arises and contributes to tumor progression in diverse cancer types. CSCs are believed to drive tumor growth and elicit resistance to conventional therapeutics. Therefore, CSCs are becoming novel target in both medical researches and clinical studies. Emerging evidences showed that nanoparticles effectively inhibit many types of CSCs by targeting various specific markers (aldehyde dehydrogenases, CD44, CD90, and CD133) and signaling pathways (Notch, Hedgehog, and TGF-β), which are critically involved in CSC function and maintenance. In this review, we briefly summarize the current status of CSC research and review a number of state-of-the-art nanomedicine approaches targeting CSC. In addition, we discuss emerging therapeutic strategies using epigenetic drugs to eliminate CSCs and inhibit cancer cell reprogramming.
- 12 April 2016
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 7, 84
Open AccessDrug Delivery Using Nanoparticles for Cancer Stem-Like Cell Targeting
The theory of cancer stem-like cell (or cancer stem cell, CSC) has been established to explain how tumor heterogeneity arises and contributes to tumor progression in diverse cancer types. CSCs are believed to drive tumor growth and elicit resistance to conventional therapeutics. Therefore, CSCs are becoming novel target in both medical researches and clinical studies. Emerging evidences showed that nanoparticles effectively inhibit many types of CSCs by targeting various specific markers (aldehyde dehydrogenases, CD44, CD90, and CD133) and signaling pathways (Notch, Hedgehog, and TGF-β), which are critically involved in CSC function and maintenance. In this review, we briefly summarize the current status of CSC research and review a number of state-of-the-art nanomedicine approaches targeting CSC. In addition, we discuss emerging therapeutic strategies using epigenetic drugs to eliminate CSCs and inhibit cancer cell reprogramming.